Generation Bio Co., a biotechnology company, discovers, develops, and commercializes redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells. It develops cell-targeted lipid nanoparticles (ctLNP) to selectively deliver small interfering RNA (siRNA) T cells to selectively delivery, intracellular, and genetically precise mechanism of target engagement could unlock a series of high-value historically undruggable disease-driving genes in autoimmunity. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
T-Cell Revolution | Generation Bio's pivot to T-cell targeting for autoimmune diseases promises innovative treatments, potentially addressing previously undruggable targets |
Moderna Partnership | Collaboration with Moderna validates technology and provides financial cushion, offering up to $1.8 billion in milestone payments and synergistic development |
Financial Landscape | Despite $158 million cash reserves, GBIO trades below cash position. Canaccord Genuity sets $9 price target, while JMP Securities maintains Market Perform rating |
Strategic Roadmap | Company aims for lead target nomination by mid-2025 and IND filing in 2026, with Phase 1 trials expected between late 2026 and early 2027 |
Metrics to compare | GBIO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGBIOPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.6x | −2.7x | −0.5x | |
PEG Ratio | −0.01 | −0.02 | 0.00 | |
Price/Book | 0.7x | 0.8x | 2.6x | |
Price / LTM Sales | 1.9x | 8.1x | 3.3x | |
Upside (Analyst Target) | - | 333.7% | 38.9% | |
Fair Value Upside | Unlock | 4.6% | 5.4% | Unlock |